Navigation Links
BioSpecifics Technologies Corp. to Present at the Stifel Nicolaus 2013 Healthcare Conference
Date:9/4/2013

LYNBROOK, N.Y., Sept. 4, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products marketed as XIAFLEX® in the U.S and XIAPEX® in the EU, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the Stifel Nicolaus 2013 Healthcare Conference at 9:10 a.m. EDT on Wednesday, September 11, 2013 in Boston, MA.

The live webcast of this presentation can be accessed under "Events & Presentation" in the Investors section of the Company's website at www.biospecifics.com or at the link http://www.veracast.com/webcasts/stifel/healthcare2013/07103451774.cfm.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is currently marketed as XIAFLEX® (collagenase clostridium histolyticum (CCH)) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium) and marketed in Europe and approved in Canada. Swedish Orphan Biovitrum AB has marketing rights for XIAPEX® (the EU trade name for CCH) for the treatment of Dupuytren's contracture and Peyronie's disease in 71 Eurasian and African countries. Asahi Kasei Pharma Corporation has development and commercialization rights for XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease in Japan and Actelion Pharmaceuticals Ltd. has development and commercialization rights for XIAFLEX for these two indications in Canada, Mexico, Brazil and Australia. CCH is in clinical development for the treatment of several additional promising indications. The PDUFA date for XIAFLEX for Peyronie's disease is December 6, 2013. Auxilium is also testing CCH for frozen shoulder syndrome and cellulite. Auxilium expects to initiate a Phase II trial of CCH for cellulite in the third quarter of this year and next stage trials of CCH for frozen shoulder syndrome in the fourth quarter of 2013. BioSpecifics is currently managing the development of CCH for the treatment of human and canine lipomas, both of which are in Phase II trials. BioSpecifics expects top-line data from these trials in the second half of the year. For more information, please visit www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2013 Financial Results
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2013 Financial Results on Thursday, August 8, 2013
3. BioSpecifics Technologies Corp. to Present at Jefferies 2013 Global Healthcare Conference
4. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013
5. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
6. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
7. BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
8. BioSpecifics Technologies Corp. to Webcast, Live, at RetailInvestorConferences.com on December 6th
9. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
10. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
11. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... Texas , June 8, 2017 /PRNewswire/ ... a leading developer and manufacturer of diagnostic ... announced today that Cressey & Company LP ... firm, has completed a growth-focused investment in ... a majority ownership position from selling shareholder, ...
(Date:6/5/2017)... The Cincinnati location of Diplomat Specialty ... has been awarded a Top Workplaces 2017 honor ... based on an employee survey administered by WorkplaceDynamics, LLC, a ... survey measures several aspects of workplace culture, including alignment, execution, ... ...
(Date:6/1/2017)... , June 1, 2017 Nutriceutical Holdings (NH), ... Recommended Solutions (VRS), and KD Pharma Group have decided ... Holdings by KD Pharma Group. KD Pharma Group will ... option to acquire the entire company. "We ... They are committed to growing the NH companies by ...
Breaking Medicine Technology:
(Date:6/25/2017)... Viejo, CA (PRWEB) , ... June 25, 2017 , ... ... any media into an old-fashioned vintage look. FCPX LUT Vintage Volume 2 contains 60 ... add film grain for distorted looks, vignettes and blurs to single out subjects, plus ...
(Date:6/25/2017)... ... ... a heatwave currently bearing down on Northern California pushing temperatures to the maximum, many people ... easy with laser hair removal. , The process of summer waxing and constantly shaving ... you want to do is get out, dive in and cool off. There is a ...
(Date:6/24/2017)... ... , ... The weather is heating up and the days are getting longer, ... aware that the summer months provide more than warmer temperatures that are perfect for ... negatively affected from direct exposure to the sun. When it comes to the security ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... their proposed healthcare bill to repeal and replace the Affordable Care Act (ACA). ... would make significant cuts to Medicaid, a public health insurance program for low-income ...
(Date:6/23/2017)... ... ... Everybody has their own personal preference when it comes to pornography. Some ... don't like it at all. FindaTopDoc took a look at what makes people attracted ... readers a taste of their deepest, darkest fantasies and has the ability to help ...
Breaking Medicine News(10 mins):